Catalyst
Slingshot members are tracking this event:
Phase 3 data of ACTIMMUNE for Friedreich's Ataxia due by end of 2016
Do you think this event is important to the companies below? How will it affect their stock price?
| Related Companies | Importance
|
Impact on Stocks
|
||||
|---|---|---|---|---|---|---|
| HZNP | Community voting in process | |||||
Additional Information
ACTIMMUNE Phase 3 Trial in Friedreich's ataxia and Phase 1 Trial in Oncology
In its pipeline, the Company continues to expect topline data in late December from the Safety, Tolerability and Efficacy of ACTIMMUNE Dose Escalation in FA (STEADFAST) Phase 3 clinical trial.
Slingshot Insights Explained
Catalyst Date
Occurred on:
Dec 08, 2016
Occurred Source:
http://ir.horizon-pharma.com/releasedetail.cfm?ReleaseID=1003338
Related Projects
- Discussing Horizon's drug ACTIMMUNE for the ultra-orphan neurologic disease, Friedreich's ataxia HZNP, Edison Executed On: Aug 29, 2016 at 01:00 PM EDT
Related Keywords
Phase 3 Data, Actimmune, Friedreich's Ataxia, Fa
